R&F Capital Advisors’s Array Biopharma Inc ARRY Stock Holding History

R&F Capital Advisors’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-13,998	Closed	-$123K	–	887
2016 Q4	$123K	Buy	+13,998	New	+$103K	0.04%	444

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

R&F Capital Advisors's ARRY Position: Q1 2017 in Review

R&F Capital Advisors sold out of Array Biopharma Inc (ARRY) in Q1 2017, closing a stake of 13,998 shares — an estimated $123K sold.

R&F Capital Advisors first reported a position in ARRY in Q4 2016 and held it in 1 quarter. The position peaked at $123K in Q4 2016. 187 funds tracked by Wall St. Rank hold ARRY as of Q1 2017.

R&F Capital Advisors reported no remaining Array Biopharma Inc position as of Q1 2017 after selling out during the quarter.
R&F Capital Advisors sold 13,998 Array Biopharma Inc shares in Q1 2017, an estimated $123K.
R&F Capital Advisors first reported a position in Array Biopharma Inc in Q4 2016 and held it in 1 quarter.
R&F Capital Advisors's Array Biopharma Inc position peaked at $123K in Q4 2016.
187 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.